Molecular Partners Ag (MOLN) Cash from Financing Activities (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Cash from Financing Activities of -$372.89 for Q1 2026, down 11.01% year-over-year from -$419.02 in Q1 2025, and up 99.97% quarter-over-quarter from -$1.4 million in Q4 2025.
Molecular Partners Ag (MOLN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Cash from Financing Activities for 7 consecutive years, with -$372.89 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 11.01% year-over-year to -$372.89; the TTM figure through Mar 2026 stood at -$1.4 million (down 108.57% YoY), while the FY2025 annual figure was -$1.4 million, down 108.73% from the prior year.
- Cash from Financing Activities grew to -$372.89 in Q1 2026 per MOLN's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $16.5 million in Q4 2024 and bottomed at -$1.6 million in Q4 2022.
- Historically, Cash from Financing Activities has averaged $714893.9 across 5 years, with a median of -$343.7 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 523.64% — and 2024, when it surged 1353.31%.
- Molecular Partners Ag's Cash from Financing Activities stood at -$1.6 million in 2022, then climbed by 19.27% to -$1.3 million in 2023, then jumped by 1353.31% to $16.5 million in 2024, then sank by 108.72% to -$1.4 million in 2025, then jumped by 99.97% to -$372.89 in 2026.
- Business Quant data shows MOLN's Cash from Financing Activities at -$372.89 in Q1 2026, -$1.4 million in Q4 2025, and $680248.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -372.89 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -372.89 |
| Mar 31, 2026 | -372.89 |
| Dec 31, 2025 | -1.44 Mn |
| Dec 31, 2025 | -1.44 Mn |
| Sep 30, 2025 | 680,248.34 |
| Sep 30, 2025 | 680,248.34 |
| Jun 30, 2025 | -657,935.39 |
| Jun 30, 2025 | -657,935.39 |
| Mar 31, 2025 | -335.90 |
| Mar 31, 2025 | -335.90 |
| Dec 31, 2024 | 16.48 Mn |
| Dec 31, 2024 | 16.48 Mn |
| Sep 30, 2024 | 653,433.66 |
| Sep 30, 2024 | 653,433.66 |
| Jun 30, 2024 | -626,653.17 |
| Jun 30, 2024 | -626,653.17 |
| Mar 31, 2024 | -343.70 |
| Mar 31, 2024 | -343.70 |
| Dec 31, 2023 | -1.31 Mn |
| Dec 31, 2023 | -1.31 Mn |